TY - JOUR T1 - Consensus on COVID-19 vaccination in pediatric oncohematological patients, on behalf of infectious working group of Italian Association of Pediatric Hematology Oncology JF - medRxiv DO - 10.1101/2022.01.06.22268792 SP - 2022.01.06.22268792 AU - Simone Cesaro AU - Paola Muggeo AU - Daniele Zama AU - Monica Cellini AU - Katia Perruccio AU - Antonella Colombini AU - Francesca Carraro AU - Mariagrazia Petris AU - Valeria Petroni AU - Maurizio Mascarin AU - Francesco Baccelli AU - Elena Soncini AU - Rosamaria Mura AU - Milena Laspina AU - Nunzia Decembrino AU - Roberta Burnelli AU - Stefano Frenos AU - Elio Castagnola AU - Maura Faraci AU - Cristina Meazza AU - Federica Barzaghi AU - Maria Rosaria D’Amico AU - Maria Capasso AU - Elisabetta Calore AU - Ottavio Ziino AU - Angelica Barone AU - Francesca Compagno AU - Laura Luti AU - Federica Galaverna AU - Raffaella De Santis AU - Letizia Brescia AU - Linda Meneghello AU - Angelamaria Petrone AU - Nagua Giurici AU - Fabian Schumacher AU - Federico Mercolini Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/08/2022.01.06.22268792.abstract N2 - Vaccines represent the best tool to prevent the severity course and fatal consequences of pandemic by new Coronavirus 2019 infection (SARS-CoV-2). Considering the limited data on vaccination of pediatric oncohematological patients, we develop a Consensus document to support the Italian pediatric hematological oncological (AIEOP) centers in a scientifically correct communication with families and patients and to promote vaccination. The topics of the Consensus were: SARS-CoV-2 infection and disease (COVID-19) in the pediatric subjects; COVID-19 vaccines (type, schedule); which and when to vaccinate; contraindications and risk of serious adverse events; rare adverse events; third dose and vaccination after COVID-19; and other general prevention measures. Using the Delphi methodology for Consensus, 21 statements and their corresponding rationale were elaborated and discussed with the representatives of 31 centers, followed by voting. AIEOP Centers showed an overall agreement on all the statements that were therefore approved.This consensus document highlights that children and adolescents affected by hematological and oncological diseases are a fragile category. Vaccination plays an important role to prevent COVID-19, to permit the regular administration of chemotherapy or other treatments, to perform control visits and hospital admissions, and to prevent treatment delays.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscrip ER -